CoChat

GLP-1 agonists for weight loss: pharmacology and clinical implications.

The DOI matches its Crossref record; 29 of the 32 references it cites were found in a registry or an index.

Abstract

This review investigates the various pharmacologic treatments for overweight and obesity in adults, especially glucagon-like peptide 1 (GLP-1) agonists. In light of the globally expanding obesity pandemic and the limited selection of treatments, physicians must be equipped with knowledge regarding proven medications and their nuanced differences to best support patients on their path to a healthier lifestyle. In this review, we explore the current medical therapies for obesity, including all major categories, individual mechanisms of action, pharmacokinetics and pharmacodynamics, adverse effects, risks, and absolute contraindications. Additionally, we review the evidence of four recent clinical trials, two systematic reviews, and two meta-analyses describing the efficacy of GLP-1 agonists in decreasing weight, lowering HbA1c, and improving obesity comorbidities. We also discuss total cost and cost-effectiveness compared to other categories, long-term adherence, barriers to use, and reasons for discontinuation of this drug category. Our goal is that this review can serve as a framework to aid providers in building their knowledge and selecting the most advantageous weight loss medication for each patient.

Overview

Integrity signals

Registry

Crossref · 10.1007/s12325-022-02394-w

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 29 references

Research works printed but not linked: 3

  1. Sombra LRS, Anastasopoulou C. Pharmacologic therapy for obesity. StatPearls Internet. Treasure Island: StatPearls; 2021. https://www.ncbi.nlm.nih.gov/books/NBK562269/. Accessed 9 Jun 2022.
  2. Tchang BG, Aras M, Kumar RB, et al. Pharmacologic treatment of overweight and obesity in adults. Endotext. South Dartmouth: MDtext.com; 2021.
  3. Collins L, Costello RA. Glucagon-like peptide-1 receptor agonists. StatPearls Internet. Treasure Island: StatPearls; 2022. https://www.ncbi.nlm.nih.gov/books/NBK551568/. Accessed 9 Jun 2022.

Cited by

See all 99

Metadata

Authors
Moore, P. W., Malone, K., VanValkenburg, D., Rando, L. L., Williams, B. C., Matejowsky, H. G., Ahmadzadeh, S., Shekoohi, S., Cornett, E. M., & Kaye, A. D.
Affiliations
  • Louisiana State University (US)
  • Louisiana State University Health Sciences Center New Orleans (US)
Corresponding author
Cornett, Elyse M.
Venue
Advances in Therapy
Published
2022-12-24
Volume
40
Issue
3
Pages
723-742
ISSN
  • 0741-238X (ISSN-L)
  • 1865-8652
OpenAlex
W4312140562
Cited by
86
References
32
Citations by year
2026: 30 · 2025: 30 · 2024: 18 · 2023: 8
FWCI
2.01
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Advances in Therapy (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
GLP-1 receptor agonists, obesity treatment, weight loss, pharmacokinetics, pharmacodynamics, adverse effects, contraindications, HbA1c reduction, obesity-related comorbidities, cost-effectiveness, medication adherence, drug discontinuation
MeSH terms
Glucagon-Like Peptide-1 Receptor, Adult, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Weight Loss, Overweight, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP-1 agonists for weight loss: pharmacology and clinical implications. https://app.cochat.ai/papers/10.1007/s12325-022-02394-w
The paper
Moore, P. W., Malone, K., VanValkenburg, D., Rando, L. L., Williams, B. C., Matejowsky, H. G., Ahmadzadeh, S., Shekoohi, S., Cornett, E. M., & Kaye, A. D. (2023). GLP-1 agonists for weight loss: pharmacology and clinical implications. Advances in Therapy. https://doi.org/10.1007/s12325-022-02394-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.